



(51) International Patent Classification:

C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/IB2019/054500

(22) International Filing Date:

30 May 2019 (30.05.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/679,611 01 June 2018 (01.06.2018) US
62/684,046 12 June 2018 (12.06.2018) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).(72) Inventors: **ABUJOUR, Aida**; c/o Novartis Institutes for
Biomedical Research, Inc., 250 Massachusetts Avenue,
Cambridge, Massachusetts 02139 (US). **BLANKENSHIP,
John**; c/o Novartis Institutes for Biomedical Research,
Inc., 250 Massachusetts Avenue, Cambridge, Massachu-
setts 02139 (US). **FLEMING, Tony**; c/o Novartis Institutes
for Biomedical Research, Inc., 250 Massachusetts Avenue,
Cambridge, Massachusetts 02139 (US). **HOLMBERG,**

Brian; c/o Novartis Institutes for Biomedical Research,
Inc., 250 Massachusetts Avenue, Cambridge, Massachu-
setts 02139 (US). **HONG, Connie**; c/o Novartis Institutes
for Biomedical Research, Inc., 250 Massachusetts Avenue,
Cambridge, Massachusetts 02139 (US). **HUANG, Lu**; c/
o Novartis Institutes for Biomedical Research, Inc., 250
Massachusetts Avenue, Cambridge, Massachusetts 02139
(US). **LU, Haihui**; c/o Novartis Institutes for Biomed-
ical Research, Inc., 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139 (US).

(74) Agent: **NOVARTIS AG**; Lichtstrasse 35, 4056 Basel
(CH).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: BINDING MOLECULES AGAINST BCMA AND USES THEREOF




FIG. 1A

(57) **Abstract:** The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(88) Date of publication of the international search report:

13 February 2020 (13.02.2020)